CB Insights Blog The next big cancer tech acquisition could be one of these 5 liquid biopsy players

As pharma companies invest in precision oncology, liquid biopsies — which enable real-time, non-invasive tumor profiling through simple blood draws — stand to improve patient adherence, which remains as low as 60% for some common tests like colorectal cancer screening. … The post The next big cancer tech acquisition could be one of these 5 liquid biopsy players appeared first on CB Insights Research.